LAS VEGAS, NV, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced, together with its joint venture partner and global biotechnology company Austrianova, the successful completion of comprehensive adventitious agent and viral testing of its GMP Master Cell Bank (MCB), from which its Working Cell Bank (WCB) was recently established. With the testing completed and the WCB now successfully established, Avaí Bio and Austrianova have completed an important milestone in the development of the Company’s genetically modified α-Klotho-producing cell line.